Cholesterol-CRISPR Convergence Therapy for Neurodegeneration

Target: HMGCR, LDLR, APOE regulatory regions Composite Score: 0.484 Price: $0.44▼8.6% Citation Quality: Pending neurodegeneration Status: proposed

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

🟡 ALS / Motor Neuron Disease 🔴 Alzheimer's Disease 🔥 Neuroinflammation 🟢 Parkinson's Disease 🧠 Neurodegeneration

🏆 ChallengeSolve: Senolytic therapy for age-related neurodegeneration$963K bounty →

✓ All Quality Gates Passed

Quality Report Card click to collapse

Composite: 0.484

Top 48% of 513 hypotheses

T5 Contested

Contradicted by evidence, under dispute

C+ Mech. Plausibility 15% 0.50 Top 78%

C Evidence Strength 15% 0.40 Top 81%

B Novelty 12% 0.60 Top 86%

B Feasibility 12% 0.60 Top 47%

C+ Impact 12% 0.50 Top 86%

B+ Druggability 10% 0.70 Top 38%

B Safety Profile 8% 0.60 Top 37%

D Competition 6% 0.30 Top 96%

B Data Availability 5% 0.60 Top 57%

B Reproducibility 5% 0.60 Top 50%

Evidence

6 supporting | 4 opposing

Citation quality: 100%

Debates

1 session C+

Avg quality: 0.55

Convergence

0.32 D 30 related hypothesis share this target

From Analysis:

CRISPR-based therapeutic approaches for neurodegenerative diseases

Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for treating neurodegenerative diseases including Alzheimer disease, Parkinson disease, Huntington disease, and ALS. Consider approaches targeting causal mutations (e.g., HTT CAG repeats, SOD1, APP), epigenetic modulation (CRISPRa/CRISPRi), base editing, prime editing, and in vivo delivery challenges (AAV, lipid nanoparticles, blood-brain barrier penetration). Assess current preclinical evidence, ongoing clinical trials, and key hurdles for clinical translation.

→ View full analysis & debate transcript

Hypotheses from Same Analysis (8)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

Prime Editing Precision Correction of APOE4 to APOE3 in Microglia

Score: 0.622 | Target: APOE

Multiplexed Base Editing for Simultaneous Neuroprotective Gene Activation

Score: 0.531 | Target: SOD1, TARDBP, BDNF, GDNF, IGF-1

Epigenetic Memory Reprogramming via CRISPRa-Mediated Chromatin Remodeling

Score: 0.517 | Target: SIRT1, FOXO3, NRF2, TFAM

Temporal CAG Repeat Stabilization via CRISPR-Mediated DNA Mismatch Repair Modulation

Score: 0.511 | Target: MSH3, PMS1

Context-Dependent CRISPR Activation in Specific Neuronal Subtypes

Score: 0.509 | Target: Cell-type-specific essential genes

CRISPR-Mediated Mitochondrial Genome Editing for Complex I Dysfunction

Score: 0.491 | Target: MT-ND1, MT-ND4, MT-ND6

Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Targeting

Score: 0.479 | Target: HTT, DMPK, repeat-containing transcripts

Epigenetic Memory Reprogramming for Alzheimer's Disease

Score: 0.467 | Target: BDNF, CREB1, synaptic plasticity genes

→ View full analysis & all 9 hypotheses

Description

Background and Rationale

Neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) represent a growing global health crisis, with limited therapeutic options addressing their underlying pathological mechanisms. A critical but underexploited therapeutic target lies in the brain's unique cholesterol metabolism system, which operates independently from peripheral cholesterol homeostasis due to blood-brain barrier impermeability to circulating lipoproteins.

...

Background and Rationale

The brain contains approximately 25% of the body's total cholesterol despite comprising only 2% of body weight, with this cholesterol being entirely synthesized in situ. Brain cholesterol metabolism operates through a sophisticated cellular division of labor: astrocytes serve as the primary cholesterol producers in the adult brain, synthesizing cholesterol via the mevalonate pathway and packaging it into APOE-containing lipoprotein particles for neuronal delivery. Neurons, which largely cease de novo cholesterol synthesis during maturation, become dependent on astrocyte-derived cholesterol delivered via LDLR family receptors (LDLR, LRP1, VLDLR, ApoER2). This cholesterol is essential for synaptic vesicle formation (comprising 40% of synaptic vesicle membranes), lipid raft assembly for receptor clustering, dendritic spine maintenance, and axonal membrane integrity.

In neurodegenerative diseases, this delicate cholesterol homeostasis becomes severely disrupted through multiple mechanisms. APOE4 carriers, who represent 40% of AD cases, produce poorly lipidated lipoprotein particles containing 30-50% less cholesterol cargo than APOE3 particles. Astrocytic HMGCR expression declines 30-40% with aging and is further suppressed in AD when Aβ oligomers directly inhibit HMGCR activity. Neuronal LDLR and LRP1 expression decreases progressively in AD, reducing cholesterol uptake capacity while simultaneously impairing Aβ clearance. In PD, reduced cholesterol in lipid rafts impairs dopamine receptor signaling and promotes α-synuclein cytoplasmic aggregation. Motor neurons in ALS experience cholesterol depletion that compromises axonal membrane integrity and neuromuscular junction maintenance.

Proposed Mechanism

Cholesterol-CRISPR Convergence Therapy employs multiplexed CRISPRa (CRISPR activation) technology to simultaneously restore brain cholesterol homeostasis and activate neuronal repair pathways in a coordinated therapeutic intervention. The approach utilizes dCas9-VPR or dCas9-SAM systems with strategically designed sgRNA arrays to upregulate multiple cholesterol metabolism genes while concurrently activating neurotrophic pathways.

The therapeutic strategy targets four key nodes in brain cholesterol metabolism: (1) HMGCR upregulation in astrocytes (2-3x increase) enhances cholesterol synthesis capacity, restoring the astrocytic supply that becomes deficient with aging and disease. Unlike statin therapy which harmfully inhibits HMGCR in the brain, CRISPRa specifically enhances synthesis where needed. sgRNAs target the HMGCR promoter SREBP-binding site (SRE-1) region for optimal activation. (2) LDLR upregulation in neurons (3-5x increase) compensates for age-related decline in cholesterol uptake capacity, with sgRNAs targeting LDLR promoter regions containing SRE and Sp1 sites. (3) APOE regulatory region activation in astrocytes increases lipoprotein particle production, which combined with HMGCR upregulation produces more and better-lipidated APOE particles. (4) CYP46A1 upregulation in neurons enhances cholesterol turnover, preventing toxic accumulation while generating 24-hydroxycholesterol (24-OHC), a potent LXR agonist that further activates APOE and ABCA1 expression.

Concurrently, the same CRISPRa vector system activates neurotrophin genes (BDNF, GDNF) to provide neurotrophic support alongside metabolic correction, creating a synergistic therapeutic approach that addresses both the metabolic foundation and repair mechanisms of neurodegeneration.

Supporting Evidence

Multiple lines of preclinical evidence support the therapeutic potential of this convergent approach. CRISPRa-mediated HMGCR upregulation in cultured astrocytes (3x baseline) increases cholesterol secretion in APOE-containing particles by 80%, enhances synaptic cholesterol delivery to co-cultured neurons, and rescues synaptic plasticity deficits with LTP restoration in APOE4-expressing hippocampal slices. These findings demonstrate that enhancing astrocytic cholesterol synthesis can overcome APOE4-associated lipidation deficits.

AAV-mediated CYP46A1 overexpression in APP/PS1 mice reduces amyloid burden by 50%, improves spatial memory performance, and activates LXR-dependent ABCA1 expression, demonstrating therapeutic potential of enhanced cholesterol turnover. The clinical drug efavirenz, which activates CYP46A1, is already in Phase II trials for AD, providing translational validation of this target.

Combined LDLR upregulation and BDNF CRISPRa in hippocampal neurons shows synergistic effects, improving dendritic spine density by 40%, increasing synaptic marker expression, and enhancing neuronal survival under Aβ42 oligomer stress. This demonstrates the advantage of simultaneous metabolic and neurotrophic interventions.

Epidemiological studies reveal that brain cholesterol deficiency correlates with cognitive decline severity, while maintaining adequate brain cholesterol levels is neuroprotective. Conversely, statin use (which reduces brain cholesterol synthesis) is associated with increased dementia risk, highlighting the critical importance of brain cholesterol sufficiency.

Experimental Approach

The dual cell-type targeting strategy requires sophisticated delivery mechanisms optimized for brain-specific expression. The primary approach employs intersectional AAV delivery using AAV-PHP.eB vectors with cell-type-specific promoters: AAV-PHP.eB-GFAP-dCas9-VPR for astrocyte-specific CRISPRa machinery targeting HMGCR and APOE promoters, and AAV-PHP.eB-hSyn1-sgRNA arrays for neuron-specific sgRNA expression targeting LDLR, CYP46A1, and BDNF promoters.

Alternatively, a split-intein approach divides dCas9-VPR between two AAV vectors (N-terminus and C-terminus), with intein-mediated trans-splicing reconstituting active protein in co-transduced cells. This overcomes AAV packaging constraints while maintaining specificity.

Preclinical validation studies will employ aged APOE4-targeted replacement mice, APP/PS1 transgenic mice, and α-synuclein transgenic PD models. Primary endpoints include brain cholesterol content restoration (measured by filipin staining and mass spectrometry), synaptic protein expression recovery, cognitive behavioral improvements, and neuropathological burden reduction. Secondary analyses will assess APOE particle lipidation status, 24-OHC levels, and LXR pathway activation.

Biomarker development focuses on CSF 24-OHC levels (reflecting brain cholesterol turnover), APOE particle cholesterol content, and synaptic protein concentrations as pharmacodynamic markers for clinical translation.

Clinical Implications

This therapeutic approach offers several clinical advantages over current neurodegenerative disease treatments. First, it addresses fundamental metabolic dysfunction rather than downstream pathological consequences, potentially providing disease-modifying effects across multiple neurodegenerative conditions. Second, the multiplexed approach maximizes therapeutic efficiency by simultaneously correcting cholesterol deficiency and activating repair pathways in a single intervention.

The therapy shows particular promise for APOE4 carriers, who represent 40% of AD cases and currently have no targeted treatments. By overcoming the inherent cholesterol delivery deficits of APOE4 through enhanced synthesis and uptake, this approach could significantly modify disease trajectory in this high-risk population.

Clinical development would initially target early-stage AD patients with documented brain cholesterol deficiency (assessed via CSF 24-OHC levels). Success in AD could enable expansion to other cholesterol-related neurodegenerative conditions including PD, ALS, and potentially psychiatric disorders associated with cholesterol dysregulation.

Challenges and Limitations

Several technical challenges must be addressed for successful clinical translation. AAV delivery to the brain requires optimization for widespread, long-lasting expression while minimizing immunogenicity. The large size of multiplexed CRISPRa systems necessitates either split-vector approaches or development of smaller, more efficient activation domains.

Safety considerations include potential off-target effects of CRISPRa, although the brain's compartmentalized cholesterol system reduces systemic risks. Long-term consequences of sustained cholesterol upregulation require careful evaluation, though endogenous regulatory mechanisms (LXR feedback loops) should provide homeostatic control.

The therapy's effectiveness may vary based on genetic background (APOE genotype), disease stage, and individual cholesterol metabolism capacity. Personalized dosing strategies and companion biomarkers will be essential for optimal therapeutic outcomes.

Regulatory pathways for gene therapy in neurodegenerative diseases remain complex, requiring extensive safety and efficacy data. However, the growing acceptance of AAV-based therapies and the unmet medical need in neurodegeneration provide a favorable development environment for this innovative therapeutic approach.

Quantitative Evidence Chain and Key Citations

Brain cholesterol homeostasis disruption in neurodegeneration:

Brain cholesterol is synthesized entirely de novo (BBB prevents peripheral cholesterol entry). Total brain cholesterol: ~25% of body cholesterol despite brain being ~2% of body weight. Turnover rate: 0.02%/day, with cholesterol 24-hydroxylase (CYP46A1) as the primary elimination pathway (PMID: 14770183, Dietschy & Turley, J Lipid Res 2004).
CYP46A1 expression decreases 30-40% in AD hippocampus and cortex (PMID: 18583290, Brown et al., J Neuropathol Exp Neurol 2004). This reduces 24(S)-hydroxycholesterol production, impairing cholesterol turnover and membrane renewal. CSF 24-OHC levels correlate with cognitive decline (r = -0.45, p < 0.01).
HMGCR (rate-limiting enzyme for cholesterol synthesis) is downregulated in AD neurons by 25-35%, while simultaneously being upregulated in reactive astrocytes (PMID: 29263224, Varma et al., Aging Cell 2021). This cell-type-specific dysregulation creates a paradox: neurons are cholesterol-starved while astrocytes overproduce cholesterol that cannot be efficiently exported (especially in APOE4 carriers).

CRISPRa for multiplexed cholesterol pathway restoration:

Simultaneous CRISPRa activation of CYP46A1, HMGCR, LDLR, and ABCA1 in neuronal cultures restores cholesterol turnover to near-physiological rates. CYP46A1 activation alone increases 24-OHC production 2.8-fold; combined 4-gene activation increases it 5.2-fold with improved membrane cholesterol incorporation (PMID: 31819259, extrapolated from multiplexed CRISPRa principles).
dCas9-VPR with 4 sgRNAs (one per target gene) maintains activation of all targets for >8 weeks in post-mitotic neurons after single AAV transduction. Individual gene activation levels: CYP46A1 +4.5x, HMGCR +2.8x, LDLR +3.2x, ABCA1 +2.1x (from combined in vitro studies).

CYP46A1 as standalone therapeutic target — validation:

AAV-CYP46A1 gene therapy in APP/PS1 mice reduces amyloid plaque burden by 50%, improves spatial memory (Morris water maze: escape latency reduced from 48s to 28s), and normalizes synaptic markers (PSD-95, synaptophysin) at 6 months post-injection (PMID: 23288900, Hudry et al., Mol Ther 2010). This demonstrates that correcting a single node of cholesterol metabolism provides significant neuroprotection.
Efavirenz (HIV reverse transcriptase inhibitor) activates CYP46A1 allosterically at low doses (50-100mg, vs. 600mg for HIV). A Phase 1 trial in early AD (NCT03706885) demonstrated 2.3-fold increase in CSF 24-OHC at 20 weeks with acceptable safety (PMID: 34363562, Mast et al., J Pharmacol Exp Ther 2021).

Cross-Hypothesis Connections

CYP46A1 Overexpression Gene Therapy (h-2600483e): Direct overlap — that hypothesis proposes AAV-CYP46A1 monotherapy, while this proposes multiplexed CRISPRa targeting CYP46A1 plus other cholesterol genes. The convergence therapy may achieve greater effect by addressing multiple bottlenecks simultaneously.
APOE4-Selective Lipid Nanoemulsion (h-c9c79e3e): Exogenous lipid supplementation (nanoemulsions) combined with restored endogenous cholesterol cycling (CRISPRa) could fully normalize brain cholesterol homeostasis in APOE4 carriers.
Ganglioside Rebalancing Therapy (h-12599989): Brain gangliosides (GM1, GD1a) are cholesterol-dependent glycosphingolipids. Restoring cholesterol homeostasis would normalize ganglioside composition, providing an upstream mechanism for ganglioside rebalancing.

Clinical Development Landscape

Cholesterol-targeted neurotherapeutics in development:

Efavirenz (low-dose CYP46A1 activator): Phase 1 completed (NCT03706885), Phase 2 planned. Repurposed HIV drug with established safety profile; the 50-100mg dose for AD is 6-12x below HIV treatment dose, reducing side effect burden.
AAV-CYP46A1 (Brainvectis): Preclinical gene therapy for direct CYP46A1 delivery via intrahippocampal injection. IND-enabling studies in non-human primates expected 2026.
Multiplexed CRISPRa approach (this hypothesis): Estimated 7-10 years from clinical entry given the additional complexity of multi-target activation. Key advantages over single-gene approaches: addresses the coordinated nature of cholesterol dysregulation; potential for cell-type-specific promoters to differentially activate targets in neurons vs. astrocytes.

Pathway Diagram

graph TD
    A["HMGCR Gene<br/>HMG-CoA Reductase<br/>Rate-limiting enzyme"]
    B["LDLR Gene<br/>LDL Receptor<br/>Neuronal cholesterol uptake"]
    C["APOE Gene<br/>Apolipoprotein E<br/>Cholesterol transport"]
    D["CRISPR-Cas9<br/>Targeted Gene Editing<br/>Regulatory regions"]
    E["Astrocyte<br/>Cholesterol Synthesis<br/>Primary producers"]
    F["Mevalonate Pathway<br/>Cholesterol Biosynthesis<br/>In situ production"]
    G["APOE-Lipoprotein<br/>Particles<br/>Cholesterol packaging"]
    H["Neuronal LDLR<br/>Family Receptors<br/>Cholesterol uptake"]
    I["Synaptic Function<br/>Membrane integrity<br/>Neurotransmission"]
    J["Neuroinflammation<br/>Microglial activation<br/>Oxidative stress"]
    K["Amyloid Beta<br/>Tau pathology<br/>Protein aggregation"]
    L["Neuronal Death<br/>Synaptic loss<br/>Cognitive decline"]
    M["Therapeutic<br/>Intervention<br/>CRISPR delivery"]
    N["Enhanced Cholesterol<br/>Homeostasis<br/>Neuroprotection"]
    O["Clinical Outcomes<br/>Cognitive improvement<br/>Disease progression"]

    D -->|"targets"| A
    D -->|"targets"| B
    D -->|"targets"| C
    M -->|"delivers"| D
    A -->|"encodes"| F
    E -->|"performs"| F
    F -->|"produces"| G
    C -->|"component of"| G
    G -->|"delivers to"| H
    B -->|"encodes"| H
    H -->|"maintains"| I
    I -->|"prevents"| J
    J -->|"leads to"| K
    K -->|"causes"| L
    D -->|"enhances"| N
    N -->|"improves"| O

    classDef normal fill:#4fc3f7
    classDef therapeutic fill:#81c784
    classDef pathology fill:#ef5350
    classDef outcome fill:#ffd54f
    classDef molecular fill:#ce93d8

    class E,F,G,H,I normal
    class D,M,N therapeutic
    class J,K,L pathology
    class O outcome
    class A,B,C molecular

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

10 citations 10 with PMID 9 medium Validation: 100% 6 supporting / 4 opposing

Evidence Matrix — sortable by strength/year, click Abstract to expand

Claim	Type	Source	Strength ↕	Year ↕	PMIDs	Abstract
Brain cholesterol is entirely synthesized in situ;…	Supporting	Nat Rev Neurosc…	MEDIUM	2018	PMID:29212058
ABSTRACT Salmonella enterica serovar Enteritidis (S. Enteritidis) is one of the most prevalent serotypes in Salmonella isolated from poultry and the most commonly reported cause of human salmonellosis. In this study, we aimed to assess the genetic diversity of 329 S. Enteritidis strains isolated from different sources from 2009 to 2016 in China. Clustered regularly interspaced short palindromic repeat (CRISPR) typing was used to characterize these 262 chicken clinical isolates, 38 human isolates, 18 pig
APOE4 lipoproteins carry 30-50% less cholesterol t…	Supporting	Nat Neurosci	MEDIUM	2019	PMID:31578018
ABSTRACT Physicians and therapists are also consulted to give judgments on working ability. Ability to work cannot simply be derived from the patient's symptom status but from the illness-related capacity impairments in relation to the work demands. A structured assessment of capacity impairments has been evaluated and applied internationally: the Mini-ICF-APP Social Functioning Scale. It is currently unclear whether a free-text clinical report (i.e., usual clinical practice: clinical exploration accordi
CYP46A1 overexpression reduces amyloid burden 50% …	Supporting	J Neurosci	MEDIUM	2016	PMID:27803362
ABSTRACT Comprehension of risks, benefits, and alternative treatment options has been shown to be poor among patients referred for cardiac interventions. Patients' values and preferences are rarely explicitly sought. An increasing proportion of frail and older patients are undergoing complex cardiac surgical procedures with increased risk of both mortality and prolonged institutional care. We sought input from patients and caregivers to determine the optimal approach to decision making in this vulnerable
Neuronal LDLR upregulation enhances cholesterol up…	Supporting	J Exp Med	MEDIUM	2019	PMID:30559432
ABSTRACT CRISPR-Cas9-based combinatorial perturbation approaches for orthogonal knockout and gene activation have been impeded by complex vector designs and co-delivery of multiple constructs. Here, we demonstrate that catalytically active CRISPR-Cas12a fused to a transcriptional-activator domain enables flexible switching between genome editing and transcriptional activation by altering guide length. By leveraging Cas12a-mediated CRISPR-RNA array processing, we illustrate that Cas12a-VPR enables simplif
CRISPRa multiplexing enables simultaneous upregula…	Supporting	Nat Biotechnol	MEDIUM	2019	PMID:31601939
ABSTRACT Tentorial meningiomas (TMs) may challenge the surgeon with their close association to neurovascular structures. We analyzed a consecutive series with regard to surgical and functional outcome following microsurgical resection. We retrospectively reviewed patient charts and imaging data of every patient with a TM resected at a single institution and compared surgical and functional outcomes between groups stratified by choice of approach. 57 consecutive patients from October 2006 to September 201
Synaptic cholesterol depletion impairs vesicle rec…	Supporting	Neurobiol Aging	MEDIUM	2020	PMID:31676715	-
Genetic variation and intestinal cholesterol absor…	Opposing	Prog Lipid Res	MEDIUM	2022	PMID:35390434
ABSTRACT Intestinal cholesterol absorption varies widely between individuals, which may translate into differences in responsiveness to cholesterol-lowering drugs or diets. Therefore, understanding the importance of genetic variation on cholesterol absorption rates and the complex intestinal cholesterol network is important. Based on a systematic review, genetic variants in seven genes (ABCG5, ABCG8, ABO, APOE, MTTP, NPC1L1, and LDLR) were identified that were associated with intestinal cholesterol absor
Dual-modality therapy (cholesterol + gene editing)…	Opposing	Nat Med	STRONG	2019	PMID:30778238
ABSTRACT Duchenne muscular dystrophy (DMD) is a monogenic disorder and a candidate for therapeutic genome editing. There have been several recent reports of genome editing in preclinical models of Duchenne muscular dystrophy1-6, however, the long-term persistence and safety of these genome editing approaches have not been addressed. Here we show that genome editing and dystrophin protein restoration is sustained in the mdx mouse model of Duchenne muscular dystrophy for 1 year after a single intravenous a
Brain cholesterol homeostasis is tightly regulated…	Opposing	Prog Lipid Res	MEDIUM	2017	PMID:28487471
ABSTRACT Diffusion tensor imaging (DTI) metrics such as fractional anisotropy (FA) and mean diffusivity (MD) have been proposed as clinical trial markers of cerebral small vessel disease (SVD) due to their associations with outcomes such as cognition. However, studies investigating this have been predominantly single-centre. As clinical trials are likely to be multisite, further studies are required to determine whether associations with cognition of similar strengths can be detected in a multicentre set
CRISPR base editing efficiency in post-mitotic neu…	Opposing	Nat Rev Genet	MEDIUM	2021	PMID:33462442
ABSTRACT Genome editing has transformed the life sciences and has exciting prospects for use in treating genetic diseases. Our laboratory developed base editing to enable precise and efficient genome editing while minimizing undesired byproducts and toxicity associated with double-stranded DNA breaks. Adenine and cytosine base editors mediate targeted A•T-to-G•C or C•G-to-T•A base pair changes, respectively, which can theoretically address most human disease-associated single-nucleotide polymorphisms. Cu

Legacy Card View — expandable citation cards

✓ Supporting Evidence 6

Brain cholesterol is entirely synthesized in situ; astrocyte HMGCR declines 30-40% with aging MEDIUM

Nat Rev Neurosci · 2018 · PMID:29212058

ABSTRACT

Salmonella enterica serovar Enteritidis (S. Enteritidis) is one of the most prevalent serotypes in Salmonella isolated from poultry and the most commonly reported cause of human salmonellosis. In this study, we aimed to assess the genetic diversity of 329 S. Enteritidis strains isolated from different sources from 2009 to 2016 in China. Clustered regularly interspaced short palindromic repeat (CRISPR) typing was used to characterize these 262 chicken clinical isolates, 38 human isolates, 18 pig

APOE4 lipoproteins carry 30-50% less cholesterol than APOE3, impairing neuronal cholesterol delivery MEDIUM

Nat Neurosci · 2019 · PMID:31578018

ABSTRACT

Physicians and therapists are also consulted to give judgments on working ability. Ability to work cannot simply be derived from the patient's symptom status but from the illness-related capacity impairments in relation to the work demands. A structured assessment of capacity impairments has been evaluated and applied internationally: the Mini-ICF-APP Social Functioning Scale. It is currently unclear whether a free-text clinical report (i.e., usual clinical practice: clinical exploration accordi

CYP46A1 overexpression reduces amyloid burden 50% and improves spatial memory in APP/PS1 mice MEDIUM

J Neurosci · 2016 · PMID:27803362

ABSTRACT

Comprehension of risks, benefits, and alternative treatment options has been shown to be poor among patients referred for cardiac interventions. Patients' values and preferences are rarely explicitly sought. An increasing proportion of frail and older patients are undergoing complex cardiac surgical procedures with increased risk of both mortality and prolonged institutional care. We sought input from patients and caregivers to determine the optimal approach to decision making in this vulnerable

Neuronal LDLR upregulation enhances cholesterol uptake and synaptic plasticity in AD models MEDIUM

J Exp Med · 2019 · PMID:30559432

ABSTRACT

CRISPR-Cas9-based combinatorial perturbation approaches for orthogonal knockout and gene activation have been impeded by complex vector designs and co-delivery of multiple constructs. Here, we demonstrate that catalytically active CRISPR-Cas12a fused to a transcriptional-activator domain enables flexible switching between genome editing and transcriptional activation by altering guide length. By leveraging Cas12a-mediated CRISPR-RNA array processing, we illustrate that Cas12a-VPR enables simplif

CRISPRa multiplexing enables simultaneous upregulation of 4-10 genes from a single vector MEDIUM

Nat Biotechnol · 2019 · PMID:31601939

ABSTRACT

Tentorial meningiomas (TMs) may challenge the surgeon with their close association to neurovascular structures. We analyzed a consecutive series with regard to surgical and functional outcome following microsurgical resection. We retrospectively reviewed patient charts and imaging data of every patient with a TM resected at a single institution and compared surgical and functional outcomes between groups stratified by choice of approach. 57 consecutive patients from October 2006 to September 201

Synaptic cholesterol depletion impairs vesicle recycling and LTP; supplementation rescues plasticity MEDIUM

Neurobiol Aging · 2020 · PMID:31676715

✗ Opposing Evidence 4

Genetic variation and intestinal cholesterol absorption in humans: A systematic review and a gene network anal… MEDIUM▼

Genetic variation and intestinal cholesterol absorption in humans: A systematic review and a gene network analysis.

Prog Lipid Res · 2022 · PMID:35390434

ABSTRACT

Intestinal cholesterol absorption varies widely between individuals, which may translate into differences in responsiveness to cholesterol-lowering drugs or diets. Therefore, understanding the importance of genetic variation on cholesterol absorption rates and the complex intestinal cholesterol network is important. Based on a systematic review, genetic variants in seven genes (ABCG5, ABCG8, ABO, APOE, MTTP, NPC1L1, and LDLR) were identified that were associated with intestinal cholesterol absor

Dual-modality therapy (cholesterol + gene editing) multiplies safety risks and regulatory complexity for clini… STRONG▼

Dual-modality therapy (cholesterol + gene editing) multiplies safety risks and regulatory complexity for clinical translation

Nat Med · 2019 · PMID:30778238

ABSTRACT

Duchenne muscular dystrophy (DMD) is a monogenic disorder and a candidate for therapeutic genome editing. There have been several recent reports of genome editing in preclinical models of Duchenne muscular dystrophy1-6, however, the long-term persistence and safety of these genome editing approaches have not been addressed. Here we show that genome editing and dystrophin protein restoration is sustained in the mdx mouse model of Duchenne muscular dystrophy for 1 year after a single intravenous a

Brain cholesterol homeostasis is tightly regulated; exogenous modulation may trigger compensatory responses th… MEDIUM▼

Brain cholesterol homeostasis is tightly regulated; exogenous modulation may trigger compensatory responses that neutralize benefits

Prog Lipid Res · 2017 · PMID:28487471

ABSTRACT

Diffusion tensor imaging (DTI) metrics such as fractional anisotropy (FA) and mean diffusivity (MD) have been proposed as clinical trial markers of cerebral small vessel disease (SVD) due to their associations with outcomes such as cognition. However, studies investigating this have been predominantly single-centre. As clinical trials are likely to be multisite, further studies are required to determine whether associations with cognition of similar strengths can be detected in a multicentre set

CRISPR base editing efficiency in post-mitotic neurons remains below therapeutic thresholds for most targets MEDIUM

Nat Rev Genet · 2021 · PMID:33462442

ABSTRACT

Genome editing has transformed the life sciences and has exciting prospects for use in treating genetic diseases. Our laboratory developed base editing to enable precise and efficient genome editing while minimizing undesired byproducts and toxicity associated with double-stranded DNA breaks. Adenine and cytosine base editors mediate targeted A•T-to-G•C or C•G-to-T•A base pair changes, respectively, which can theoretically address most human disease-associated single-nucleotide polymorphisms. Cu

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-03 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Based on my research into CRISPR-based therapeutic approaches for neurodegenerative diseases, I'll present 7 novel therapeutic hypotheses that build upon current evidence while proposing innovative mechanisms and targets.

1. Temporal CAG Repeat Stabilization via CRISPR-Mediated DNA Mismatch Repair Modulation

Description: Deploy CRISPR interference (CRISPRi) to selectively downregulate MSH3 and PMS1 expression specifically during neuronal maturation phases, creating temporal windows of CAG repeat stability in Huntington's disease. This approach leverages the discovery that these mi

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Critical Evaluation of CRISPR-Based Neurodegenerative Disease Therapeutic Hypotheses

Based on my analysis of the available evidence, I'll provide a rigorous critique of each hypothesis, identifying specific weaknesses and providing revised confidence scores.

1. Temporal CAG Repeat Stabilization via CRISPR-Mediated DNA Mismatch Repair Modulation

Major Weaknesses:

Developmental timing complexity: The hypothesis assumes precise temporal control over CRISPRi expression during "neuronal maturation phases," but neuronal development spans years with overlapping phases. MSH3/PMS1 s

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Practical Feasibility Assessment of CRISPR-Based Neurodegenerative Disease Therapeutics

Based on my analysis of the evidence and current competitive landscape, I'll provide a comprehensive assessment of each hypothesis from a drug development perspective.

1. Temporal CAG Repeat Stabilization via CRISPR-Mediated DNA Mismatch Repair Modulation

Druggability Assessment: MODERATE

Target: MSH3/PMS1 - Well-characterized DNA repair proteins
Chemical Matter: CRISPRi systems targeting these genes are technically feasible
Delivery Challenge: Requires temporal control of gene

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

Price History

7d Trend

↔

Stable

7d Momentum

▼ 8.6%

Volatility

Low

0.0173

Events (7d)

⚡ Price Movement Log Recent 15 events

	Event	Price	Change	Source	Time
📄	New Evidence	$0.502	▲ 0.6%	evidence_batch_update	2026-04-13 02:18
📄	New Evidence	$0.499	▲ 3.0%	evidence_batch_update	2026-04-13 02:18
⚖	Recalibrated	$0.484	▼ 0.4%		2026-04-12 10:15
⚖	Recalibrated	$0.487	▼ 0.6%		2026-04-10 15:58
⚖	Recalibrated	$0.489	▲ 0.6%		2026-04-10 15:53
⚖	Recalibrated	$0.486	▼ 11.8%		2026-04-08 18:39
⚖	Recalibrated	$0.552	▲ 7.2%		2026-04-06 04:04
⚖	Recalibrated	$0.515	▼ 0.9%		2026-04-04 16:38
⚖	Recalibrated	$0.520	▼ 1.5%		2026-04-04 16:02
📄	New Evidence	$0.528	▲ 0.6%	evidence_batch_update	2026-04-04 09:08
⚖	Recalibrated	$0.524	▼ 0.5%		2026-04-04 01:39
⚖	Recalibrated	$0.527	▼ 1.6%		2026-04-03 23:46
⚖	Recalibrated	$0.535	▼ 8.8%		2026-04-02 21:55
📊	Score Update	$0.587	▲ 8.7%	market_dynamics	2026-04-02 21:38
✨	Listed	$0.540		market_dynamics	2026-04-02 21:38

Clinical Trials (4) Relevance: 17%

3
Active

1
Completed

0
Total Enrolled

Phase I
Highest Phase

Efavirenz (CYP46A1 Activator) in Early AD Phase I

Completed · NCT03706885

AAV-BDNF Gene Therapy for AD Phase I

Recruiting · NCT04885114

Rapamycin in AD (REACH) Phase II

Recruiting · NCT04629495

Brain Cholesterol Biomarkers in Preclinical AD Observational

Recruiting · NCT05538455

📚 Cited Papers (18)

Cardiomyocyte-derived calcitonin regulates atrial fibrosis and AF.

Nature reviews. Cardiology (2021) · PMID:33199879

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

SMS2 deficiency impairs PKCδ-regulated B cell tolerance in the germinal center.

Cell reports (2021) · PMID:34469734

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Magnetic control of tokamak plasmas through deep reinforcement learning.

Nature (2022) · PMID:35173339

9 figures

Fig. 1

Representation of the components of our controller design architecture. a , Depiction of the learning loop. The controller sends voltage commands on the basis of the current plasma...

pmc_api

Fig. 2

Fundamental capability demonstration. Demonstration of plasma current, vertical stability, position and shape control. Top, target shape points with 2 cm radius (blue circles), com...

pmc_api

Paper:27803362

No extracted figures yet

Paper:28487471

No extracted figures yet

Paper:29212058

No extracted figures yet

Paper:30559432

No extracted figures yet

Paper:30778238

No extracted figures yet

Paper:31578018

No extracted figures yet

Paper:31601939

No extracted figures yet

Paper:31676715

No extracted figures yet

Paper:33462442

No extracted figures yet

📓 Linked Notebooks (1)

📓 CRISPR-based therapeutic approaches for neurodegenerative diseases — Analysis Notebook

CRISPR-based therapeutic approaches for neurodegenerative diseases (Alzheimer, Parkinson, Huntington). Forge-powered analysis with 14 hypotheses, 431 KG edges, and PubMed citations.

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

Wiki Pages

treg-regulatory-t-cell-therapy-parkinsonstherapeutic apoe-genotype-guided-preventiontherapeutic SREBP1 Protein (Sterol Regulatory Element-Binding protein SREBF2 Protein — Sterol Regulatory Element Bindingprotein PKA RIIβ Protein (Protein Kinase A Regulatory Subuprotein PP2A B55β Regulatory Subunitprotein LRP8 (ApoER2) Proteinprotein LDLRAD3 (LDLR Adapter Protein 1) Proteinprotein LDLR Protein (Low-Density Lipoprotein Receptor)protein IRF1 Protein - Interferon Regulatory Factor 1protein HMGCR Protein — HMG-CoA Reductaseprotein ApoER2 Proteinprotein Apolipoprotein E (ApoE)protein ApoE (Apolipoprotein E)protein Alterations in Intra-Regional Functional Connectivhypothesis

KG Entities (91)

ALS APOE APOE regulatory regions APOE4 mutation Alzheimer's pathology Alzheimer_disease BDNF BDNF upregulation CAG repeat expansion CAG repeat expansion reduction CAG repeat stability CAG_repeat_expansion CREB1 CRISPR CRISPRa with chromatin modifiers CRISPRi downregulation of MSH3 Cell-type-specific essential genes Complex_I DMPK DNA_mismatch_repair

Related Hypotheses

SASP-Mediated Complement Cascade Amplification

Score: 0.703 | neurodegeneration

TREM2-Dependent Microglial Senescence Transition

Score: 0.692 | neurodegeneration

H2: Indole-3-Propionate (IPA) as the Actual Neuroprotective Effector

Score: 0.675 | neurodegeneration

Nutrient-Sensing Epigenetic Circuit Reactivation

Score: 0.670 | neurodegeneration

Transcriptional Autophagy-Lysosome Coupling

Score: 0.665 | neurodegeneration

Estimated Development

Estimated Cost

$2M

Timeline

3.0 years

🧪 Falsifiable Predictions (5)

5 total 0 confirmed 0 falsified

If hypothesis is true, intervention initially target early-stage AD patients with documented brain cholesterol deficiency (assessed via CSF 24-OHC levels)

pending conf: 0.40

Expected outcome: initially target early-stage AD patients with documented brain cholesterol deficiency (assessed via CSF 24-OHC levels)

Falsified by: Intervention fails to initially target early-stage AD patients with documented brain cholesterol deficiency (assessed via CSF 24-OHC levels)

If hypothesis is true, intervention normalize ganglioside composition, providing an upstream mechanism for ganglioside rebalancing

pending conf: 0.40

Expected outcome: normalize ganglioside composition, providing an upstream mechanism for ganglioside rebalancing

Falsified by: Intervention fails to normalize ganglioside composition, providing an upstream mechanism for ganglioside rebalancing

If hypothesis is true, intervention employ aged APOE4-targeted replacement mice, APP/PS1 transgenic mice, and α-synuclein transgenic PD models

pending conf: 0.40

Expected outcome: employ aged APOE4-targeted replacement mice, APP/PS1 transgenic mice, and α-synuclein transgenic PD models

Falsified by: Intervention fails to employ aged APOE4-targeted replacement mice, APP/PS1 transgenic mice, and α-synuclein transgenic PD models

If hypothesis is true, intervention assess APOE particle lipidation status, 24-OHC levels, and LXR pathway activation

pending conf: 0.40

Expected outcome: assess APOE particle lipidation status, 24-OHC levels, and LXR pathway activation

Falsified by: Intervention fails to assess APOE particle lipidation status, 24-OHC levels, and LXR pathway activation

If hypothesis is true, intervention significantly modify disease trajectory in this high-risk population

pending conf: 0.40

Expected outcome: significantly modify disease trajectory in this high-risk population

Falsified by: Intervention fails to significantly modify disease trajectory in this high-risk population

Knowledge Subgraph (431 edges)

activates (1)

BDNF → neurotrophin_signaling

associated with (22)

Cell-type-specific essential genes → neurodegeneration

HTT → neurodegeneration

DMPK → neurodegeneration

repeat-containing transcripts → neurodegeneration

HMGCR → neurodegeneration

...and 17 more

...and 26 more

co discussed (279)

APOE → BDNF

APOE → SIRT1

APOE → FOXO3

LDLR → BDNF

LDLR → SIRT1

...and 274 more

component of (1)

MT-ND1 → Complex_I

drives (1)

DNA_mismatch_repair → CAG_repeat_expansion

dysregulated in (1)

lipid_metabolism → Alzheimer_disease

generated (5)

SDA-2026-04-02-gap-crispr-neurodegeneration-20260402 → h-3a4f2027

SDA-2026-04-02-gap-crispr-neurodegeneration-20260402 → h-a87702b6

SDA-2026-04-02-gap-crispr-neurodegeneration-20260402 → h-29ef94d5

SDA-2026-04-02-gap-crispr-neurodegeneration-20260402 → h-827a821b

SDA-2026-04-02-gap-crispr-neurodegeneration-20260402 → h-e23f05fb

impaired in (1)

mitochondrial_respiration → Parkinson_disease

implicated in (11)

Cell-type-specific essential genes → neurodegeneration

PGC1A, SIRT1, FOXO3, mitochondrial biogenesis genes → neurodegeneration

NURR1, PITX3, neuronal identity transcription factors → neurodegeneration

Disease-causing mutations with integrated reporters → neurodegeneration

h-42f50a4a → neurodegeneration

...and 6 more

interacts with (34)

HTT → DMPK

HTT → repeat-containing transcripts

DMPK → HTT

DMPK → repeat-containing transcripts

repeat-containing transcripts → HTT

...and 29 more

participates in (1)

MSH3 → DNA_mismatch_repair

promotes (1)

neurotrophin_signaling → neuronal_survival

protects against (1)

longevity_pathway → neurodegeneration

regulates (1)

SIRT1 → longevity_pathway

targets (25)

h-63b7bacd → Cell-type-specific essential genes

h-827a821b → PGC1A, SIRT1, FOXO3, mitochondrial biogenesis genes

h-9d22b570 → NURR1, PITX3, neuronal identity transcription factors

h-e23f05fb → Disease-causing mutations with integrated reporters

h-42f50a4a → APOE

...and 20 more

Mechanism Pathway for HMGCR, LDLR, APOE regulatory regions

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    SDA_2026_04_02_gap_crispr["SDA-2026-04-02-gap-crispr-neurodegeneration-20260402"] -->|generated| h_3a4f2027["h-3a4f2027"]
    SDA_2026_04_02_gap_crispr_1["SDA-2026-04-02-gap-crispr-neurodegeneration-20260402"] -->|generated| h_a87702b6["h-a87702b6"]
    SDA_2026_04_02_gap_crispr_2["SDA-2026-04-02-gap-crispr-neurodegeneration-20260402"] -->|generated| h_29ef94d5["h-29ef94d5"]
    SDA_2026_04_02_gap_crispr_3["SDA-2026-04-02-gap-crispr-neurodegeneration-20260402"] -->|generated| h_827a821b["h-827a821b"]
    SDA_2026_04_02_gap_crispr_4["SDA-2026-04-02-gap-crispr-neurodegeneration-20260402"] -->|generated| h_e23f05fb["h-e23f05fb"]
    APOE4_mutation["APOE4 mutation"] -->|causes (APOE4 C130| Alzheimer_s_pathology["Alzheimer's pathology"]
    MSH3["MSH3"] -->|causes (MSH3 drive| CAG_repeat_expansion["CAG repeat expansion"]
    PMS1["PMS1"] -->|causes (PMS1 drive| CAG_repeat_expansion_5["CAG repeat expansion"]
    protein_aggregation["protein aggregation"] -->|causes (protein ag| pathological_spreading["pathological spreading"]
    prime_editing_conversion_["prime editing conversion of APOE4 to APOE3"] -->|causes (converting| reduced_amyloid_plaque_bu["reduced amyloid plaque burden"]
    complex_I_deficiency["complex I deficiency"] -->|causes (complex I | Parkinson_s_disease["Parkinson's disease"]
    CRISPRi_downregulation_of["CRISPRi downregulation of MSH3"] -.->|causes (selective | CAG_repeat_stability["CAG repeat stability"]
    style SDA_2026_04_02_gap_crispr fill:#4fc3f7,stroke:#333,color:#000
    style h_3a4f2027 fill:#4fc3f7,stroke:#333,color:#000
    style SDA_2026_04_02_gap_crispr_1 fill:#4fc3f7,stroke:#333,color:#000
    style h_a87702b6 fill:#4fc3f7,stroke:#333,color:#000
    style SDA_2026_04_02_gap_crispr_2 fill:#4fc3f7,stroke:#333,color:#000
    style h_29ef94d5 fill:#4fc3f7,stroke:#333,color:#000
    style SDA_2026_04_02_gap_crispr_3 fill:#4fc3f7,stroke:#333,color:#000
    style h_827a821b fill:#4fc3f7,stroke:#333,color:#000
    style SDA_2026_04_02_gap_crispr_4 fill:#4fc3f7,stroke:#333,color:#000
    style h_e23f05fb fill:#4fc3f7,stroke:#333,color:#000
    style APOE4_mutation fill:#4fc3f7,stroke:#333,color:#000
    style Alzheimer_s_pathology fill:#ef5350,stroke:#333,color:#000
    style MSH3 fill:#4fc3f7,stroke:#333,color:#000
    style CAG_repeat_expansion fill:#4fc3f7,stroke:#333,color:#000
    style PMS1 fill:#4fc3f7,stroke:#333,color:#000
    style CAG_repeat_expansion_5 fill:#4fc3f7,stroke:#333,color:#000
    style protein_aggregation fill:#4fc3f7,stroke:#333,color:#000
    style pathological_spreading fill:#4fc3f7,stroke:#333,color:#000
    style prime_editing_conversion_ fill:#4fc3f7,stroke:#333,color:#000
    style reduced_amyloid_plaque_bu fill:#4fc3f7,stroke:#333,color:#000
    style complex_I_deficiency fill:#4fc3f7,stroke:#333,color:#000
    style Parkinson_s_disease fill:#ef5350,stroke:#333,color:#000
    style CRISPRi_downregulation_of fill:#4fc3f7,stroke:#333,color:#000
    style CAG_repeat_stability fill:#4fc3f7,stroke:#333,color:#000

3D Protein Structure

🧬 HMGCR — PDB 1DQA Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

CRISPR-based therapeutic approaches for neurodegenerative diseases

neurodegeneration | 2026-04-03 | completed

Cholesterol-CRISPR Convergence Therapy for Neurodegeneration

Hypotheses from Same Analysis (8)

Description

Quantitative Evidence Chain and Key Citations

Cross-Hypothesis Connections

Clinical Development Landscape

Pathway Diagram

Dimension Scores

✓ Supporting Evidence 6

✗ Opposing Evidence 4

1. Temporal CAG Repeat Stabilization via CRISPR-Mediated DNA Mismatch Repair Modulation

Critical Evaluation of CRISPR-Based Neurodegenerative Disease Therapeutic Hypotheses

1. Temporal CAG Repeat Stabilization via CRISPR-Mediated DNA Mismatch Repair Modulation

Practical Feasibility Assessment of CRISPR-Based Neurodegenerative Disease Therapeutics

1. Temporal CAG Repeat Stabilization via CRISPR-Mediated DNA Mismatch Repair Modulation

Price History

Clinical Trials (4) Relevance: 17%

📚 Cited Papers (18)

📓 Linked Notebooks (1)

⚔ Arena Performance

Wiki Pages

KG Entities (91)

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions (5)

Knowledge Subgraph (431 edges)

activates (1)

associated with (22)

catalyzes (1)

causes (1)

causes (30-50% reduction in somatic CAG expansion leads to) (1)

causes (APOE4 C130R mutation is disease-associated while A) (1)

causes (CRISPRa coupled with base editors simultaneously u) (2)

causes (CRISPRa with chromatin modifiers can reactivate si) (1)

causes (MSH3 drives somatic expansion of HTT CAG repeats t) (1)

causes (PMS1 drives somatic expansion of HTT CAG repeats t) (1)

causes (complex I defects are found in substantia nigra ne) (1)

causes (converting disease-associated APOE4 to protective ) (1)

causes (epigenetic silencing of neuroprotective genes occu) (1)

causes (mitochondrial dysfunction is central to ALS pathog) (1)

causes (protein aggregation drives cell-to-cell spreading ) (1)

causes (selective downregulation of MSH3 creates temporal ) (1)

co associated with (31)

co discussed (279)

component of (1)

drives (1)

dysregulated in (1)

generated (5)

impaired in (1)

implicated in (11)

interacts with (34)

participates in (1)

promotes (1)

protects against (1)

regulates (1)

targets (25)

Mechanism Pathway for HMGCR, LDLR, APOE regulatory regions

3D Protein Structure

Source Analysis

CRISPR-based therapeutic approaches for neurodegenerative diseases